Fremanezumab is a new medicine under development for preventative treatment of chronic and episodic migraine. It acts by targeting a very specific type of protein called the human calcitonin gene-related peptide (CGRP) which is a well-known to be involved in migraine. Therefore, if licensed it will offer a potential new treatment option for patients with migraine.
Fremanezumab for chronic and episodic migraine
Interventions:
Fremanezumab (TEV-48125; Ajovy)
Indications:
Migraine
Therapeutic Areas:
Neurology
Year:
2017